Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
about
Targeting receptor tyrosine kinases in gastric cancerThe validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing.Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry.Molecular targeting to treat gastric cancer.HER2/neu testing in primary colorectal carcinoma.Recent advances in the HER2 targeted therapy of gastric cancerRON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas.Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters.HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesQuantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.Targeted therapy in gastric cancer.HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma.Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues.C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder.Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancerBiomarkers of gastric cancer: Current topics and future perspective
P2860
Q27013050-8D5F02CC-05FD-4CAA-BED8-EFC03FAAF938Q33764191-FEC73CB4-4EC2-4D3B-A737-41F93D264F42Q34292255-DB46F7B0-FF44-4BDC-BEE7-ADF8E81E4D3FQ34326593-018BB405-37DA-425A-BA8A-525C52E4B1F6Q34499615-AE5FA7EE-B50F-4D16-8CA8-5F026A1C06EBQ34967104-4D6760F7-1E29-4441-BCC9-98CFBA1FB3AFQ35146597-04C7E6B2-F2C5-41D8-A803-3BE27CC14840Q35548468-3B98B0F7-CFA1-46DD-8EE6-AA10CCA1F241Q35831069-9BF66D65-358D-4683-AB65-78DD29DC7041Q35863874-574D40FA-A178-42EF-8B43-DA220BECF0E0Q36358687-ECB335EB-D946-4540-BC16-AF9844D71741Q36408890-C4174845-1DA9-4E68-BA55-C5083EC4D28FQ37241496-4120D7DD-949A-4BB9-BBDA-2647409C59B6Q37251780-7B3110F4-42A7-4FD5-A89D-2D8AF300CC35Q37341824-99CEB9BA-620D-4D8C-9627-B21A865A7110Q37590066-213F8BBD-4CA5-4C45-BD5C-81A893B7742CQ38402575-82195218-8910-4544-8DEE-8A4B385D7061Q39866108-553B8E8E-74E0-4CB5-941C-C1947F33752CQ53200395-5D1D5B0B-7CFE-40B0-9FF8-0854D190216DQ57072196-1BB3B770-F847-4D67-BF23-C39C259EA5D9Q57176090-745AC9B5-56F3-4BFB-81EA-16BB04DF9354
P2860
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
@en
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
@nl
type
label
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
@en
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
@nl
prefLabel
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
@en
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
@nl
P2093
P2860
P356
P1476
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
@en
P2093
Anya N A Milne
G Johan A Offerhaus
Paul J van Diest
P2860
P304
P356
10.4061/2011/674182
P577
2010-12-06T00:00:00Z